Clinica Adventista Belgrano

Arsema

Atherosclerosis

Cardiovascular Diseases

COVID-19

Severe Acute Respiratory Syndrome

Viral Pneumonia

Breast Cancer

Pneumonia

Coronavirus Infections

BGE-175

Estrogen

Fostamatinib

Olpasiran

Nivolumab

Amgen

BioAge Labs

Bristol-Myers Squibb (BMS)

Rigel Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Arsema | Clinica Adventista Belgrano

Site insights

Work at this site?

Active trials

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Trial sponsors